Assessment of saliva and gingival crevicular fluid soluble urokinase plasminogen activator receptor (suPAR), galectin-1, and TNF-α levels in periodontal health and disease.
galectin-1
gingival crevicular fluid
periodontal diseases
saliva
soluble urokinase plasminogen activator receptor
Journal
Journal of periodontal research
ISSN: 1600-0765
Titre abrégé: J Periodontal Res
Pays: United States
ID NLM: 0055107
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
13
10
2019
revised:
06
01
2020
accepted:
25
02
2020
pubmed:
14
3
2020
medline:
15
12
2020
entrez:
14
3
2020
Statut:
ppublish
Résumé
The aim of the study is to evaluate saliva and gingival crevicular fluid (GCF) levels of suPAR and galectin-1 in different periodontal health status and relationship between these molecules and TNF-α to understand the roles of these molecules in periodontal inflammation process. Soluble urokinase plasminogen activator receptor (suPAR) has been described as a biological marker of inflammation and immunological activation. Galectin-1, a member of the galectin family, is an anti-inflammatory cytokine. However, to date, levels of these two molecules in periodontal health and disease have not been well documented. A total of 60 individuals, 20 with chronic periodontitis (group P), 20 with gingivitis (group G), and 20 with healthy periodontium (group H) were recruited for this study. Full-mouth clinical periodontal measurements were recorded in periodontal charts. GCF and whole saliva samples were collected to determine the levels of suPAR, galectin-1, and TNF-α in study groups using enzymelinked immunosorbent assay (ELISA) method. The GCF total amount of suPAR, galectin-1, and TNF-α in GCF was similar in group P and G (P > .05). The GCF total amounts of these molecules in GCF were higher in the group G and P compared to the group H (P < .05), whereas the GCF concentrations of suPAR and galectin-1 were lower in the group G and P compared to the group H (P < .05).The saliva concentration of suPAR was significantly higher in group P compared to the group G and H (P < .05). It was also higher in the group G compared to the group H but there is no significant difference between the groups (P > .05). Salivary galectin-1 levels were similar in the study groups (P > .05). Increased levels of GCF suPAR, galectin-1, and saliva suPAR in periodontal disease suggest that these molecules may play a role in the periodontal inflammation. suPAR and galectin-1 may be considered as potential biomarkers in periodontal disease.
Sections du résumé
OBJECTIVE
OBJECTIVE
The aim of the study is to evaluate saliva and gingival crevicular fluid (GCF) levels of suPAR and galectin-1 in different periodontal health status and relationship between these molecules and TNF-α to understand the roles of these molecules in periodontal inflammation process.
BACKGROUND
BACKGROUND
Soluble urokinase plasminogen activator receptor (suPAR) has been described as a biological marker of inflammation and immunological activation. Galectin-1, a member of the galectin family, is an anti-inflammatory cytokine. However, to date, levels of these two molecules in periodontal health and disease have not been well documented.
METHODS
METHODS
A total of 60 individuals, 20 with chronic periodontitis (group P), 20 with gingivitis (group G), and 20 with healthy periodontium (group H) were recruited for this study. Full-mouth clinical periodontal measurements were recorded in periodontal charts. GCF and whole saliva samples were collected to determine the levels of suPAR, galectin-1, and TNF-α in study groups using enzymelinked immunosorbent assay (ELISA) method.
RESULTS
RESULTS
The GCF total amount of suPAR, galectin-1, and TNF-α in GCF was similar in group P and G (P > .05). The GCF total amounts of these molecules in GCF were higher in the group G and P compared to the group H (P < .05), whereas the GCF concentrations of suPAR and galectin-1 were lower in the group G and P compared to the group H (P < .05).The saliva concentration of suPAR was significantly higher in group P compared to the group G and H (P < .05). It was also higher in the group G compared to the group H but there is no significant difference between the groups (P > .05). Salivary galectin-1 levels were similar in the study groups (P > .05).
CONCLUSION
CONCLUSIONS
Increased levels of GCF suPAR, galectin-1, and saliva suPAR in periodontal disease suggest that these molecules may play a role in the periodontal inflammation. suPAR and galectin-1 may be considered as potential biomarkers in periodontal disease.
Substances chimiques
Galectin 1
0
Receptors, Urokinase Plasminogen Activator
0
Tumor Necrosis Factor-alpha
0
Plasminogen
9001-91-6
Urokinase-Type Plasminogen Activator
EC 3.4.21.73
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
622-630Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Page RC. The role of inflammatory mediators in the pathogenesis of periodontal disease. J Periodontal Res. 1991;26(3 Pt 2):230-242.
Ingman T, Tervahartiala T, Ding Y, et al. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin Periodontol. 1996;23(12):1127-1132.
Ejeil AL, Igondjo-Tchen S, Ghomrasseni S, Pellat B, Godeau G, Gogly B. Expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in healthy and diseased human gingiva. J Periodontol. 2003;74(2):188-195.
Yue Y, Liu Q, Xu C, et al. Comparative evaluation of cytokines in gingival crevicular fluid and saliva of patients with aggressive periodontitis. Int J Biol Markers. 2013;28(1):108-112.
Gorska R, Gregorek H, Kowalski J, Laskus-Perendyk A, Syczewska M, Madalinski K. Relationship between clinical parameters and cytokine profiles in inflamed gingival tissue and serum samples from patients with chronic periodontitis. J Clin Periodontol. 2003;30(12):1046-1052.
Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27(3-4):157-172.
Sidenius N, Sier CF, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 2000;475(1):52-56.
Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science. 2006;311(5761):656-659.
Østergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis. 2004;36(1):14-19.
Senoo T, Hattori N, Tanimoto T, et al. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax. 2010;65(4):334-340.
Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27(3):157-172.
Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268(3):296-308.
Cerinic MM, Generini S, Partsch G, et al. Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface. Life Sci. 1998;63(6):441-453.
Gustafsson A, Ajeti V, Ljunggren L. Detection of suPAR in the saliva of healthy young adults: comparison with plasma levels. Biomark Insights. 2011;6:119-125.
Skottrup PD, Dahlen G, Baelum V, Lopez R. Soluble urokinase-type plasminogen activator receptor is associated with signs of periodontitis in adolescents. Eur J Oral Sci. 2018;126(4):292-299.
Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008;10:e17.
Villa-Verde DMS, Silva-Monteiro E, Jasiulionis MG, et al. Galectin-3 modulates carbohydrate-dependent thymocyte interactions with the thymic microenvironment. Eur J Immunol. 2002;32(5):1434-1444.
Dietz AB, Bulur PA, Knutson GJ, Matasić R, Vuk-Pavlović S. Maturation of human monocyte-derived dendritic cells studied by microarray hybridization. Biochem Biophys Res Commun. 2000;275(3):731-738.
Rabinovich GA, Daly G, Dreja H, et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med. 1999;190(3):385-398.
Gil CD, Gullo CE, Oliani SM. Effect of exogenous galectin-1 on leukocyte migration: modulation of cytokine levels and adhesion molecules. Int J Clin Exp Pathol. 2010;4(1):74-84.
Cedeno-Laurent F, Opperman M, Barthel SR, Kuchroo VK, Dimitroff CJ. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol. 2012;188(7):3127-3137.
Ford P, Gemmell E, Walker P, West M, Cullinan M, Seymour G. Characterization of heat shock protein-specific T cells in atherosclerosis. Clin Diagn Lab Immunol. 2005;12(2):259-267.
Offner H, Celnik B, Bringman TS, Casentini-Borocz D, Nedwin GE, Vandenbark AA. Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. J Neuroimmunol. 1990;28(2):177-184.
Santucci L, Fiorucci S, Rubinstein N, et al. Galectin-1 suppresses experimental colitis in mice. Gastroenterology. 2003;124(5):1381-1394.
Santucci L, Fiorucci S, Cammilleri F, Servillo G, Federici B, Morelli A. Galectin-1 exerts immunomodulatory and protective effects on concanavalin a-induced hepatitis in mice. Hepatology. 2000;31(2):399-406.
Erdemir EO, Duran I, Haliloglu S. Effects of smoking on clinical parameters and the gingival crevicular fluid levels of IL-6 and TNF-alpha in patients with chronic periodontitis. J Clin Periodontol. 2004;31(2):99-104.
Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986;319(6053):516-518.
Nishikawa M, Yamaguchi Y, Yoshitake K, Saeki Y. Effects of TNFalpha and prostaglandin E2 on the expression of MMPs in human periodontal ligament fibroblasts. J Periodontal Res. 2002;37(3):167-176.
Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999;4(1):1-6.
Silness J, Loe H. Periodontal disease in pregnancy. Ii. Correlation between oral hygiene and periodontal condtion. Acta Odontol Scand. 1964;22:121-135.
Loe H. The Gingival Index, the Plaque Index and the Retention Index Systems. J Periodontol. 1967;38(6):610-616.
Kumar NN, Panchaksharappa MG, Annigeri RG. Saliva: Can it be a Supportive Marker for Oxidative Stress among Rheumatoid Arthritis Patients?. J Dent App. 2015;2(5):210-213.
Gokul K, Faizuddin M, Pradeep AR. Estimation of the level of tumor necrosis factor- alpha in gingival crevicular fluid and serum in periodontal health & disease: a biochemical study. Indian J Dent Res. 2012;23(3):348-352.
Lamster IB, Oshrain RL, Gordon JM. Enzyme activity in human gingival crevicular fluid: considerations in data reporting based on analysis of individual crevicular sites. J Clin Periodontol. 1986;13(8):799-804.
Lamster IB. Evaluation of components of gingival crevicular fluid as diagnostic tests. Ann Periodontol. 1997;2(1):123-137.
Griffiths GS. Formation, collection and significance of gingival crevice fluid. Periodontol 2000. 2003;31(1):32-42.
Uitto VJ. Gingival crevice fluid-an introduction. Periodontol 2000. 2003;31(1):9-11.
Toldi G, Beko G, Kadar G, et al. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission. Clin Chem Lab Med. 2013;51(2):327-332.
Slot O, Brunner N, Locht H, Oxholm P, Stephens RW. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis. 1999;58(8):488-492.
Nykjaer A, Moller B, Todd RF 3rd, et al. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol. 1994;152(2):505-516.
Campbell IK, Piccoli DS, Roberts MJ, Muirden KD, Hamilton JA. Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum. 1990;33(4):542-552.
Brommer EJ, Dooijewaard G, Dijkmans BA, Breedveld FC. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemost. 1992;68(2):180-184.
Pliyev BK. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol Cell Biochem. 2009;321(1-2):111-122.
Correa MP, Andrade FEC, Gimenes AD, Gil CD. Anti-inflammatory effect of galectin-1 in a murine model of atopic dermatitis. J Mol Med (Berl). 2017;95(9):1005-1015.
Cooper D, Norling LV, Perretti M. Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow. J Leukoc Biol. 2008;83(6):1459-1466.
Correa SG, Sotomayor CE, Aoki MP, Maldonado CA, Rabinovich GA. Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology. 2003;13(2):119-128.
Rabinovich GA, Ilarregui JM. Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol Rev. 2009;230(1):144-159.
Mendez-Huergo SP, Hockl PF, Stupirski JC, et al. Clinical relevance of galectin-1 and galectin-3 in rheumatoid arthritis patients: differential regulation and correlation with disease activity. Front Immunol. 2018;9:3057.
Reesink HL, Nixon AJ, Su J, et al. Galectins-1 and-3 increase in equine post-traumatic osteoarthritis. Front Vet Sci. 2018;5:288.
Ilarregui JM, Croci DO, Bianco GA, et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol. 2009;10(9):981-991.
Fuertes MB, Molinero LL, Toscano MA, et al. Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase. Mol Cell Biochem. 2004;267(1-2):177-185.
Wozniak KL, Arribas A, Leigh JE, Fidel PL Jr. Inhibitory effects of whole and parotid saliva on immunomodulators. Oral Microbiol Immunol. 2002;17(2):100-107.
Kurtis B, Tuter G, Serdar M, et al. Gingival crevicular fluid levels of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha in patients with chronic and aggressive periodontitis. J Periodontol. 2005;76(11):1849-1855.
Rossomando EF, Kennedy JE, Hadjimichael J. Tumour necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch Oral Biol. 1990;35(6):431-434.
Rasmussen LJ, Ladelund S, Haupt TH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33(11):769-775.